Back to Active Positions
NASDAQ: ASPI · Advanced Materials

ASP Isotopes

A category-defining platform in the global critical materials and isotope supply chain — powering nuclear medicine, quantum computing, and clean energy.

Founded
2021
Headquarters
Dallas, Texas
Ticker
NASDAQ: ASPI
Sector
Advanced Materials / Energy
Company Overview

Enriching the Elements That Power Civilization

ASP Isotopes Inc. (NASDAQ: ASPI) is an advanced materials company transitioning from development into commercial production of high-value isotopes and critical gases. The company employs its proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technology to produce isotopes essential to healthcare, semiconductors, and clean energy.

ASPI has commenced commercial output of Silicon-28, Carbon-14, and Ytterbium-176 at enrichment facilities in Pretoria, South Africa, with first commercial shipments expected across multiple isotopes in 2026. Through partnerships with TerraPower and Fermi America, ASPI is advancing HALEU supply for next-generation nuclear reactors via its subsidiary Quantum Leap Energy. The January 2026 acquisition of Renergen Limited added helium and LNG operations, with Phase 1 nameplate capacity expected Q3 2026. With $333 million in cash and securities and two U.S. radiopharmacy acquisitions completed, ASPI is positioned as a vertically integrated global provider of critical materials.

~$632M
Market Cap
3
Enrichment Facilities
$50–70M
Revenue Target '26–27
$333M
Cash & Securities
271
Employees Global
$37B+
HALEU Demand '37
Data as of April 13, 2026
Investment Perspective

Our Position

We hold conviction across multiple dimensions of ASPI's value creation potential.

01
Strategic Independence

The only independent Western producer of multiple critical isotopes — reducing dangerous dependency on Russia and China for materials essential to national security, healthcare, and semiconductor manufacturing.

02
Commercial Inflection

Silicon-28 and Ytterbium-176 shipments have begun — analytically validated by customers. First commercial revenue unlocking $50–70M in near-term potential across quantum computing and nuclear medicine markets.

03
$37B+ HALEU Market

TerraPower partnership provides long-duration supply visibility in the global HALEU market through 2037. Multiple SMR developers and governments now engaged as the nuclear renaissance accelerates.

04
Helium Supply Crisis

Renergen acquisition adds helium — a uniquely constrained commodity with 25–30% of global supply currently offline. Critical for semiconductors, MRI imaging, and quantum cooling infrastructure.

05
Proven Leadership

Founder-CEO Paul Mann (ex-Soros, Highbridge, Morgan Stanley) resumed leadership January 2026, calling it a "potentially transformative year." Deep technical bench across isotope enrichment and nuclear fuels.

06
Accelerating Scale

Four additional laser production plants being procured. JSE secondary listing in preparation. Revenue ramp from development-stage to commercial enterprise underway across all three verticals.

Live Intelligence Feed
ASPI Intelligence Terminal

Real-time intelligence on ASP Isotopes.

Live price, market data, milestones, and supply-chain analytics for ASP Isotopes — purpose-built to track the company's transition from development to commercial production across isotopes, HALEU, and helium.

Launch Terminal
NASDAQ: ASPI · Updated continuously
ASPI+0.42% | Si-28Commercial Shipments Q1 2026 | Yb-176Customer-Validated | HALEU$37B+ Demand by 2037 | RenergenPhase 1 Q3 2026 | Helium25–30% Supply Offline | Cash$333M | Mkt Cap~$632M | Ba-137Quantum Order Q1 2026 | Facilities3 Active · 4 Procuring | Rev Target '26–27$50–70M | ASPI+0.42% | Si-28Commercial Shipments Q1 2026 | Yb-176Customer-Validated | HALEU$37B+ Demand by 2037 | RenergenPhase 1 Q3 2026 | Helium25–30% Supply Offline | Cash$333M | Mkt Cap~$632M | Ba-137Quantum Order Q1 2026 | Facilities3 Active · 4 Procuring | Rev Target '26–27$50–70M |
Live Feed
ASPI Intelligence Terminal